Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Palomo L, et al. Among authors: sureda a. Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937. Oncotarget. 2016. PMID: 27486981 Free PMC article.
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Mateos MV, Gutiérrez NC, Martín-Ramos ML, Paiva B, Montalbán MA, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Martín A, Díaz-Mediavilla J, de Arriba F, Palomera L, Hernández JM, Sureda A, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, Fernández M, García-Sanz R, Vidriales MB, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Among authors: sureda a. Blood. 2011 Oct 27;118(17):4547-53. doi: 10.1182/blood-2011-04-345801. Epub 2011 Sep 6. Blood. 2011. PMID: 21900193 Free article. Clinical Trial.
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
Sorigue M, Mercadal S, Alonso S, Fernández-Álvarez R, García O, Moreno M, Pomares H, Alcoceba M, González-García E, Motlló C, González-Barca E, Martin A, Sureda A, Caballero D, Ribera JM, Sancho JM. Sorigue M, et al. Among authors: sureda a. Hematol Oncol. 2017 Dec;35(4):520-527. doi: 10.1002/hon.2378. Epub 2017 Feb 3. Hematol Oncol. 2017. PMID: 28156010
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Montoro J, Pomares H, Villacampa G, Merchán B, Molero A, Alonso E, Gallur L, Grau J, Salamero O, Roldán E, Saumell S, Ortega M, Sureda A, Bosch F, Arnan M, Valcárcel D. Montoro J, et al. Among authors: sureda a. Leuk Lymphoma. 2019 Jun;60(6):1522-1527. doi: 10.1080/10428194.2018.1542151. Epub 2018 Nov 30. Leuk Lymphoma. 2019. PMID: 30499738
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Sorigue M, Oliveira A, Mercadal S, Tapia G, Climent F, Perez-Roca L, Lorences I, Domingo-Domenech E, Cabezon M, Navarro JT, Gonzalez-Barca E, Zamora L, Ribera JM, Sureda A, Armengol MP, Sancho JM. Sorigue M, et al. Among authors: sureda a. Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25. Hematol Oncol. 2019. PMID: 31475375
Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions.
Mercadal S, Sancho JM, Climent F, Tapia G, Pomares H, Carro I, Sorigué M, Pané M, Domingo-Doménech E, Encuentra M, Aguilera C, Oliveira AC, Andrade M, Fernández de Sevilla A, Ribera JM, González-Barca E, Sureda A. Mercadal S, et al. Among authors: sureda a. Eur J Haematol. 2020 Mar;104(3):198-206. doi: 10.1111/ejh.13359. Epub 2019 Dec 22. Eur J Haematol. 2020. PMID: 31769545
Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis.
Parody R, Sánchez-Ortega I, Ferrá C, Guardia R, Talarn C, Encuentra M, Fort E, López D, Morgades M, Alonso E, Ortega S, Sarrá J, Gallardo D, Ribera JM, Sureda A. Parody R, et al. Among authors: sureda a. Oncol Ther. 2020 Dec;8(2):311-324. doi: 10.1007/s40487-020-00115-3. Epub 2020 May 14. Oncol Ther. 2020. PMID: 32700041 Free PMC article.
Risk factors and outcome of COVID-19 in patients with hematological malignancies.
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martínez D, Jurado M, Calbacho M, Vázquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldaña R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernández N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Piñana JL, et al. Among authors: sureda a. Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32864192 Free PMC article.
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R, Pérez-Simón JA, Moreno E, Queraltó JM, Caballero D, Mateos M, Sureda A, Cañizo C, Brunet S, Briones J, Vazquez L, Clopés A, San Miguel JF, Sierra J. Martino R, et al. Among authors: sureda a. Biol Blood Marrow Transplant. 2005 Jun;11(6):437-47. doi: 10.1016/j.bbmt.2005.03.003. Biol Blood Marrow Transplant. 2005. PMID: 15931632 Free article.
883 results